Endlyz Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $17.3M

  • Investors
  • 7

Endlyz Therapeutics General Information

Description

Developer of disease-modifying therapeutics designed to restore endo-lysosomal function and abrogate neurodegeneration. The company specializes in developing technology that restores endo-lysosomal function and abrogates neurodegeneration in Parkinson's disease (PD) and other dementias, enabling patients to prevent the disease in the early stages.

Contact Information

Website
www.endlyz.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1st Floor, 71 Kingsway
  • London WC2B 6ST
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1st Floor, 71 Kingsway
  • London WC2B 6ST
  • England, United Kingdom

Endlyz Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Endlyz Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Seed Round 28-Apr-2026 $17.3M Completed Startup
4. Debt - General 01-Feb-2023 Completed Startup
3. Seed Round 29-Jul-2021 Completed Startup
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 01-Jan-2021 Completed Startup
To view Endlyz Therapeutics’s complete valuation and funding history, request access »

Endlyz Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-3
Seed-2
Seed 3,046,154 $0.000100 8% $1 $1 1x $1 6.13%
To view Endlyz Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Endlyz Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Endlyz Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
CD3 Leuven Venture Capital Minority
Oxford Science Enterprises Venture Capital Minority
Parkinson's UK Corporation Minority
SV Health Investors PE/Buyout Minority
You’re viewing 5 of 7 investors. Get the full list »

Endlyz Therapeutics FAQs

  • When was Endlyz Therapeutics founded?

    Endlyz Therapeutics was founded in 2021.

  • Where is Endlyz Therapeutics headquartered?

    Endlyz Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Endlyz Therapeutics?

    Endlyz Therapeutics has 7 total employees.

  • What industry is Endlyz Therapeutics in?

    Endlyz Therapeutics’s primary industry is Drug Discovery.

  • Is Endlyz Therapeutics a private or public company?

    Endlyz Therapeutics is a Private company.

  • What is the current valuation of Endlyz Therapeutics?

    The current valuation of Endlyz Therapeutics is .

  • What is Endlyz Therapeutics’s current revenue?

    The current revenue for Endlyz Therapeutics is .

  • How much funding has Endlyz Therapeutics raised over time?

    Endlyz Therapeutics has raised $23.4M.

  • Who are Endlyz Therapeutics’s investors?

    AbbVie Ventures, CD3 Leuven, Oxford Science Enterprises, Parkinson's UK, and SV Health Investors are 5 of 7 investors who have invested in Endlyz Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process